723 results match your criteria Breast Care Basel[Journal]


Management of HER2-Positive Early Breast Cancer.

Breast Care (Basel) 2018 Dec 5;13(6):453-455. Epub 2018 Dec 5.

Klinik für Gynäkologie und Geburtshilfe, Helios Klinikum Berlin-Buch, Berlin, Germany.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/494945
Publisher Site
http://dx.doi.org/10.1159/000494945DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381884PMC
December 2018
1 Read

Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.

Breast Care (Basel) 2018 Dec 3;13(6):447-452. Epub 2018 May 3.

Post-Graduation Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.

Adjuvant chemotherapy has greatly improved the prognosis of early breast cancer. Dose-dense chemotherapy seeks to increase efficacy by changing the interval between cycles of treatment without the need of increasing doses and toxicity. According to the Gompertzian model, the smaller tumors are and the more rapid they grow, the more benefit could be expected from dose-dense therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381879PMC
December 2018
1 Read
0.911 Impact Factor

Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy.

Breast Care (Basel) 2018 Dec 6;13(6):440-446. Epub 2018 Nov 6.

Interdisciplinary Breast Centre, Department of Gynecology and Obstetrics, Klinikum Esslingen, Esslingen, Germany.

Background: Prediction of non-sentinel lymph node (SLN) status after primary systemic therapy (PST) may allow tailored axillary staging. The aim of this analysis was to compare established nomograms from i) the primary operative (n = 6) and ii) the neoadjuvant (n = 1) setting with an optimized nomogram to predict non-SLN status in patients after PST.

Methods: 181 patients converting from cN1 prior to PST to ycN0 but found to have a histologically positive SLN in the SENTINA trial were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489565DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381911PMC
December 2018
1 Read

Predictive Factors for Non-Sentinel Lymph Node Metastasis in Patients with ACOSOG Z0011 Criteria.

Breast Care (Basel) 2018 Dec 13;13(6):434-438. Epub 2018 Jul 13.

Instituto Alexander Fleming, Buenos Aires, Argentina.

Background: Nodal staging constitutes an element of great importance in the treatment planning for early breast cancer. The ACOSOG Z0011 trial demonstrated that sentinel lymph node (SLN) biopsy alone results in rates of local control, disease-free survival, and overall survival equivalent to those seen after axillary lymph node dissection. The purpose of this study was to determine the rate of patients that fulfill the ACOSOG Z0011 inclusion criteria and to define predictive factors for non-SLN positivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381814PMC
December 2018
2 Reads

Clinical Validation of DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.

Breast Care (Basel) 2018 Dec 28;13(6):425-433. Epub 2018 Sep 28.

Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Breast cancer patients at high risk for recurrence are treated with anthracycline-based chemotherapy, but not all patients do equally benefit from such a regimen. To further improve therapy decision-making, biomarkers predicting outcome are of high unmet medical need. The percent DNA methylation ratio (PMR) of the promoter gene coding for the Paired-like homeodomain transcription factor 2 (PITX2) was determined by a validated methylation-specific real-time polymerase chain reaction (PCR) test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381917PMC
December 2018

Gynecomastia - Conservative and Surgical Management.

Authors:
Kristin Baumann

Breast Care (Basel) 2018 Dec 14;13(6):419-424. Epub 2018 Nov 14.

Clinic for Gynecology and Obstetrics, University Medical Centre Schleswig-Holstein Campus Lübeck, Lübeck, Germany.

Gynecomastia is defined as a unilateral or bilateral persistent benign mammary gland enlargement in men. Prevalence of asymptomatic gynecomastia is up to 65%. True gynecomastia must be distinguished from pseudogynecomastia. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/494276
Publisher Site
http://dx.doi.org/10.1159/000494276DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381901PMC
December 2018
5 Reads

Granulomatous Mastitis: A Therapeutic and Diagnostic Challenge.

Breast Care (Basel) 2018 Dec 23;13(6):413-418. Epub 2018 Nov 23.

Breast Unit, Evangelische Huyssens-Stiftung, Kliniken Essen-Mitte, Essen, Germany.

Granulomatous mastitis (GM) is a rare benign inflammatory breast disease that affects mostly women of childbearing age with a history of breastfeeding. The etiopathogenesis is still unknown; however, inflammation as the result of a reaction to trauma, metabolic or hormonal processes, autoimmunity, and an infection with have all been implicated. Clinical findings are pain, mass, hyperemia, and inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381909PMC
December 2018
1 Read

Benign Breast Tumours - Diagnosis and Management.

Breast Care (Basel) 2018 Dec 14;13(6):403-412. Epub 2018 Dec 14.

Department of Gynecology and Obstetrics, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany.

With improvements in breast imaging, mammography, ultrasound and minimally invasive interventions, the detection of early breast cancer, non-invasive cancers, lesions of uncertain malignant potential, and benign lesions has increased. However, with the improved diagnostic capabilities comes a substantial risk of false-positive benign lesions and vice versa false-negative malignant lesions. A statement is provided on the manifestation, imaging, and diagnostic verification of isolated benign breast tumours that have a frequent manifestation, in addition to general therapy management recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495919DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381897PMC
December 2018
2 Reads

Benign Breast Diseases.

Authors:
Marc Thill

Breast Care (Basel) 2018 Dec 12;13(6):400-401. Epub 2018 Dec 12.

Department of Gynecology and Gynecological Oncology, Breast Center, AGAPLESION Markus Hospital, Frankfurt/M., Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495918DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381924PMC
December 2018

Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment? - A Systematic Review.

Breast Care (Basel) 2018 Oct 3;13(5):380-385. Epub 2018 May 3.

Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.

Background: Secondary lymphedema (SL) is a possible side effect of breast cancer treatment. Current data describe a positive influence of exercise on upper lymphedema. This systematic review evaluates studies examining a potential preventive effect of exercise on SL incidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257143PMC
October 2018

Nipple-Sparing Mastectomy with Primary Implant Reconstruction: Surgical and Oncological Outcome of 435 Breast Cancer Patients.

Breast Care (Basel) 2018 Oct 20;13(5):373-378. Epub 2018 Jun 20.

Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.

Background: This study aimed to examine the incidence of surgical complications associated with nipple-sparing mastectomy (NSM) with primary implant reconstruction, analyze risk factors for early and late surgical complications of NSM, and determine the incidence of local recurrences and the safety of sparing the nipple-areola complex (NAC).

Methods: This retrospective cohort study included 435 patients with 441 NSM procedures over a period of 9 years (2004-2012). All surgical complications and the oncological outcome were recorded during follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257155PMC
October 2018
7 Reads

The Warwick Experience of the Oncotype DX® Breast Recurrence Score® Assay as a Predictor of Chemotherapy Administration.

Breast Care (Basel) 2018 Oct 13;13(5):369-372. Epub 2018 Jul 13.

The Warwick Breast Unit, Warwick Hospital, Warwick, UK.

Introduction: Oncotype DX® analyses the expression of 21 genes within tumour tissue to determine a Recurrence Score® (RS). RS is a marker of risk for distant recurrence in oestrogen receptor-positive early breast cancer, allowing patient-specific benefit of chemotherapy to be evaluated. Our aim was to determine whether the introduction of Oncotype DX led to a net reduction in chemotherapy use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489131DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257137PMC
October 2018
9 Reads

Intraductal Papilloma Without Atypia on Image- Guided Breast Biopsy: Upgrade Rates to Carcinoma at Surgical Excision.

Breast Care (Basel) 2018 Oct 13;13(5):364-368. Epub 2018 Jul 13.

Institute of Radiology (RZI), Klinikum Frankfurt Höchst, Academic Teaching Hospital of the University of Frankfurt, Frankfurt/M., Germany.

Background: The management of intraductal papilloma without atypia (IDP) in breast needle biopsy remains controversial. This study investigates the upgrade rate of IDP to carcinoma and clinical and radiologic features predictive of an upgrade.

Methods: Patients with a diagnosis of IDP on image-guided (mammography, ultrasound, magnetic resonance imaging) core needle or vacuum-assisted biopsy and surgical excision of this lesion at a certified breast center between 2007 and 2017 were included in this institutional review board-approved retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257098PMC
October 2018
12 Reads

Granulomatous Lobular Mastitis: Antituberculous Treatment and Outcome in 22 Patients.

Breast Care (Basel) 2018 Oct 5;13(5):359-363. Epub 2018 Jul 5.

Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, Shandong, China.

Background: Granulomatous lobular mastitis (GLM) is a rare chronic inflammatory condition of the breast. The purpose of this study was to describe antituberculous treatment of GLM and the long-term follow-up outcome.

Methods: This retrospective study included 22 patients who had been histopathologically diagnosed with GLM at the Second Hospital of Shandong University from January 2011 to March 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487935DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257198PMC
October 2018
17 Reads

Jumping Breast Phenomenon Following Subcutaneous Mastectomy: First Description and Grading of a Well-Known Breast Deformity.

Breast Care (Basel) 2018 Oct 3;13(5):354-358. Epub 2018 Aug 3.

Breast Unit, Evangelische Huyssens-Stiftung, Kliniken Essen-Mitte, Essen, Germany.

Introduction: One of the goals of breast cancer surgery is to preserve the breast. However, where this is not possible, various breast reconstructive procedures are available. The most common procedure is the immediate insertion of a subpectoral implant after removing the breast tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489939DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257146PMC
October 2018
1 Read

New Technologies for Sentinel Lymph Node Detection.

Authors:
Amit Goyal

Breast Care (Basel) 2018 Oct 18;13(5):349-353. Epub 2018 Sep 18.

Department of Surgery, Royal Derby Hospital, Derby, UK.

The 'standard of care' method for sentinel node mapping is the combination technique using radioisotope and blue dye although some centres use radioisotope or blue dye alone. Radioisotope usage requires licensing, has regulatory issues around handling and disposal of waste, and logistically may be unavailable or difficult to implement in some centres or less developed country. This has led to the development of alternative methods such as superparamagnetic iron oxide (SPIO), fluorescence techniques using indocyanine green (ICG) or fluorescein, computed tomography lymphography, and contrast-enhanced ultrasound scan (CEUS) using microbubbles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257081PMC
October 2018
21 Reads

Lymph Nodes in Breast Cancer - What Can We Learn from Translational Research?

Breast Care (Basel) 2018 Oct 25;13(5):342-347. Epub 2018 Sep 25.

Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany.

Clinical observations about lack of survival benefit after extensive axillary surgery and biological discordance between primary breast tumors and axillary lymph nodes raise the question of the actual metastatic potential of axillary nodal disease. The exploration of intratumoral heterogeneity and detection of genomic differences between the primary and lymph nodes indicate some similarity between the number of mutations in synchronous axillary node metastases and those in the primary lesion, suggesting a favorable prognosis. The hematogenous route of metastasis needs to be considered in findings of different subclones between nodal and distant metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492435DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257149PMC
October 2018

Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting.

Breast Care (Basel) 2018 Oct 26;13(5):337-341. Epub 2018 Sep 26.

Department of Surgery, Capio St. Göran's Hospital, Stockholm, Sweden.

Axillary surgery has undergone considerable changes in recent years, especially in relation to patients who undergo neoadjuvant chemotherapy (NACT). Due to constantly decreasing rates of recurrence and death from breast cancer, modern surgical strategies aim at de-escalating the extent of local treatment and avoiding unnecessary procedures. This relates especially to lymph node surgery which is associated with considerable morbidity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257201PMC
October 2018
3 Reads

What Is the Best Management of cN0pN1(sn) Breast Cancer Patients?

Breast Care (Basel) 2018 Oct 5;13(5):331-336. Epub 2018 Sep 5.

Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany.

Although the majority of breast cancer patients are clinically node-negative (cN0) at diagnosis, 15-20% will have a metastatic sentinel lymph node (SLN, pN1(sn)). While a less radical approach regarding axillary surgery in cN0 patients with a positive SLN biopsy is advocated, the limitations of 5 published trials on axillary management in pN1(sn) are discussed intensely in the literature and support the performance of ongoing validation and extension trials, especially considering the lack of data in the setting of mastectomy. As locoregional radiotherapy has a significant effect on both recurrence and survival, a standardization of locoregional radiotherapy in the situation of SLN biopsy alone in pN1(sn) patients has to be defined in the future, and de-escalation trials should embrace a truly multidisciplinary approach. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/491704
Publisher Site
http://dx.doi.org/10.1159/000491704DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257152PMC
October 2018
14 Reads

Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery?

Breast Care (Basel) 2018 Oct 24;13(5):324-330. Epub 2018 Aug 24.

Breast Surgery Unit, San Raffaele University and Research Hospital, Milan, Italy.

Local treatment of the axilla in clinically node-negative (cN0) early breast cancer patients with routine sentinel lymph node biopsy (SLNB) is debated for various reasons: i) pN staging information may not be necessary for the postoperative treatment decision regarding adjuvant systemic therapy in the great majority of patients; ii) the SLNB-positive rate is declining below 20% in specialized breast centers; iii) albeit being a minimally invasive procedure, SLNB causes a significant reduction in quality of life in 23% of patients; and iv) previous randomized trials from the pre-SLNB era did not show a disadvantage for patients without axillary surgery with regard to overall survival. These data support the hypothesis that avoiding axillary treatment in patients with clinically and sonographically unsuspicious lymph nodes seems to be a safe option, although omitting axillary surgery may increase the risk of locoregional recurrence. Currently, the information regarding node-positive status is essential to guide postoperative treatment such as systemic or radiation therapies in a non-negligible minority of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257084PMC
October 2018
2 Reads

Lymph Node Management in Breast Cancer: A Highly Dynamic Evolution.

Authors:
Thorsten Kühn

Breast Care (Basel) 2018 Oct 12;13(5):320-322. Epub 2018 Oct 12.

Department of Gynecology and Obstetrics, Klinikum Esslingen, Esslingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257206PMC
October 2018

News from ASCO 2018.

Breast Care (Basel) 2018 Aug 12;13(4):298-302. Epub 2018 Jul 12.

University Clinic of Internal Medicine III, Paracelsus Medical University, Salzburg, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491564DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167691PMC
August 2018
1 Read

Primary Rhabdomyosarcoma of the Breast: Imaging Findings and Literature Review.

Breast Care (Basel) 2018 Aug 22;13(4):293-297. Epub 2018 May 22.

Pediatric Radiology Division, Radiology Department, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.

Background: Primary breast rhabdomyosarcoma (RMS) can occur in children. There is a lack of knowledge regarding radiologic findings and added diffusion-weighted magnetic resonance imaging (MRI) features of RMS in the literature.

Case Report: A 12-year-old girl was diagnosed with primary alveolar RMS of the breast. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/487750
Publisher Site
http://dx.doi.org/10.1159/000487750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167649PMC
August 2018
11 Reads
0.911 Impact Factor

Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer.

Breast Care (Basel) 2018 Aug 24;13(4):285-291. Epub 2018 May 24.

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Radiation therapy (RT) for breast cancer has dramatically changed over the past years, leading to individualized risk-adapted treatment strategies. Historically, the choice of RT regimen was limited to conventional fractionation protocols using standard tangential fields. Nowadays, technological and technical improvements in modern RT have added a variety of other RT modalities, different fractionation schedules, and individualised treatment volumes to the portfolio of breast RT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170912PMC
August 2018
3 Reads

Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.

Breast Care (Basel) 2018 Aug 13;13(4):277-283. Epub 2018 Jul 13.

Medical Oncology Department, Salamanca Clinic University Hospital, Salamanca, Spain.

The optimal sequence of anti-human epidermal growth factor receptor 2 (HER2) therapies in metastatic breast cancer (MBC) is still undetermined. Physicians must therefore make decisions based on clinical trials and their own experience for the best treatment sequence in these patients. The objective of this review is to summarize the efficacy and safety data for trastuzumab emtansine (T-DM1) in patients with MBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170918PMC
August 2018
1 Read

Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients.

Breast Care (Basel) 2018 Aug 3;13(4):272-276. Epub 2018 May 3.

Department of Gynecology and Obstetrics, University Medical Center Mainz, Mainz, Germany.

Background: Low-dose metronomic chemotherapy (LDMC) is increasingly used in metastatic breast cancer (MBC). In this retrospective analysis, we examined the therapeutic effects and side effects of LDMC in a cohort of MBC patients.

Methods: Patients with MBC were included when LDMC with oral cyclophosphamide (CTX) and methotrexate (MTX) was administered between 2009 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170902PMC

Prevalence of Cardiac Disease in Breast Cancer Patients at Time of Diagnosis Compared to the General Female Population in Germany.

Breast Care (Basel) 2018 Aug 29;13(4):264-271. Epub 2018 Mar 29.

Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany.

Background: Advances in oncological therapy have significantly improved breast cancer survival; therefore comorbid conditions are becoming more relevant. We investigated the prevalence of prior cardiovascular diseases and risk factors in patients with breast cancer compared to those in the general female population in Germany.

Methods: The PASSOS heart study is a retrospective multicenter cohort study on cardiac late effects in breast cancer patients treated between 1998 and 2008. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/487261
Publisher Site
http://dx.doi.org/10.1159/000487261DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170908PMC
August 2018
4 Reads

Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.

Breast Care (Basel) 2018 Aug 14;13(4):251-262. Epub 2018 Aug 14.

Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

For decades, the neoadjuvant setting has provided a useful scenario for research in breast cancer. Historically, neoadjuvant clinical trials, either hormone therapy-based or chemotherapy-based, have tried to recapitulate the results of their counterpart adjuvant studies, but with smaller patient numbers, more rapid outcomes (clinical response and/or pathologic complete response (pCR)), together with additional biologic information. As for neoadjuvant chemotherapy trials, the increase in pCR rates has been recently accepted as an appropriate surrogate marker to accelerate drug approval in high-risk breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170905PMC
August 2018
4 Reads

Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer.

Breast Care (Basel) 2018 Aug 3;13(4):244-249. Epub 2018 Aug 3.

Breast Cancer Unit, Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.

Neoadjuvant treatment allows us to improve surgical results and test new drugs. In recent years, there have been significant advances in the field of neoadjuvant treatment, including hormonal neoadjuvant therapy in luminal tumors, double blockade in HER2-positive tumors, and the use of platinum salts in triple-negative tumors. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/491759
Publisher Site
http://dx.doi.org/10.1159/000491759DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170899PMC
August 2018
12 Reads

Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy.

Breast Care (Basel) 2018 Aug 25;13(4):238-243. Epub 2018 Jul 25.

Obstetrics and Gynecology Department, Hospital Universitari Son Espases, Palma, Spain.

Neoadjuvant therapy (NAT) allows downstaging in some cases of breast cancer. By consequence, it may enable a more conservative surgical approach or make surgery possible in cases ineligible for surgery before NAT. In this article, we review the evidence and management recommendations for optimal surgical treatment in this setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491760DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167713PMC

From Standard of Care to the Neoadjuvant Model as an Innovative Platform for Exploring Promising Combinations in Breast Cancer.

Authors:
Cristina Saura

Breast Care (Basel) 2018 Aug 24;13(4):236-237. Epub 2018 Aug 24.

Breast Cancer Unit, Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167678PMC

PARP Inhibitors in Breast Cancer: Why, How, and When?

Breast Care (Basel) 2018 Jul 20;13(3):216-219. Epub 2018 Jun 20.

Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062717PMC
July 2018
19 Reads

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018.

Breast Care (Basel) 2018 07 22;13(3):209-215. Epub 2018 May 22.

Abteilung für Konservative und Molekulare Gynäkologische Onkologie, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsklinikum Mainz, Mainz, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062660PMC
July 2018
1 Read

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018.

Breast Care (Basel) 2018 07 15;13(3):196-208. Epub 2018 Jun 15.

Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062659PMC
July 2018
1 Read

A Case Report of Triple-Positive Micropapillary Carcinoma of the Male Breast.

Breast Care (Basel) 2018 Jul 8;13(3):192-194. Epub 2018 Mar 8.

Center for Nuclear Medicine and Radiotherapy (CENAR), Quetta, Pakistan.

Background: Micropapillary carcinoma (MPC), a morphologically distinct subtype of invasive ductal carcinoma, of the male breast is an exceedingly uncommon disease.

Case Report: Herein, we report a case of triple-positive MPC of the male breast with axillary lymph node involvement and no recurrence for over 2 years. Specifically, a 60-year-old male patient presented with a hard, elastic, and well-defined painless mass in the right breast. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062662PMC
July 2018
5 Reads

Effects of Music Intervention on the Physical and Mental Status of Patients with Breast Cancer: A Systematic Review and Meta-Analysis.

Breast Care (Basel) 2018 Jul 6;13(3):183-190. Epub 2018 Jun 6.

School of Public Health and Management, Chongqing Medical University, Chongqing, China.

Background: The aim of this review was to evaluate the effects of music intervention on the physical and mental status of patients with breast cancer.

Methods: 9 databases were searched; 30 randomized controlled trials that compared the effects of music plus standard care and standard care alone in patients with breast cancer were included. Methodological quality was assessed using the Jadad scale. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/487073
Publisher Site
http://dx.doi.org/10.1159/000487073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062713PMC
July 2018
16 Reads

Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial.

Breast Care (Basel) 2018 Jul 26;13(3):177-181. Epub 2018 Apr 26.

Division of Medical Senology, European Institute of Oncology, Milan, Italy.

Background: Few data are available on the benefit of metronomic cyclophosphamide, capecitabine, and vinorelbine as first-line therapy in patients with metastatic triple-negative breast cancer.

Methods: This phase II study assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine 40 mg orally 3 times a week, cyclophosphamide 50 mg daily, and capecitabine 500 mg 3 times a day (VEX regimen) in untreated metastatic triple-negative breast cancer patients. The biopsy of the metastatic site had to be triple-negative, independent of the hormone receptor expression of the primary tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062718PMC
July 2018
1 Read

Lymph Node Radiotherapy Instead of Extended Axillary Surgery - the New Standard?

Breast Care (Basel) 2018 Jul 6;13(3):173-175. Epub 2018 Jun 6.

Department of Radiation Oncology, Sana Klinikum Offenbach, Offenbach, Germany.

Breast cancer treatment has undergone major changes in the last 20 years. Specifically, the role of axillary lymph node dissection has changed from radical axillary dissection with excision of a high number of lymph nodes to sentinel lymph node biopsy (SLNB). This paradigm shift is associated with a controversial debate regarding the significance of axillary staging, the need for surgery, and the role of radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062724PMC
July 2018
22 Reads

Proton Therapy for Primary Breast Cancer.

Authors:
Eugen B Hug

Breast Care (Basel) 2018 Jul 15;13(3):168-172. Epub 2018 Jun 15.

MedAustron Ion Therapy Center, Wiener Neustadt, Austria.

Proton therapy reduces the integral dose received by normal tissues due to its physical properties of dose deposition in the Bragg peak. In a small but significant percentage of patients requiring adjuvant radiotherapy (RT) for left-sided breast cancer, photon-based RT can lead to cardiac complications during long-term follow-up. The risk of cardiac complications is correlated with the dose to the coronary arteries and to the general 'mean heart dose'. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489893DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062734PMC
July 2018
1 Read

Intraoperative Electron Radiotherapy (IOERT) in the Treatment of Primary Breast Cancer.

Breast Care (Basel) 2018 Jul 30;13(3):162-167. Epub 2018 May 30.

Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria.

IOERT (intraoperative electron radiotherapy) in breast cancer is used either as a boost (10-12 Gy) followed by whole breast irradiation (WBI) or as full-dose partial breast irradiation (PBI, 20-24 Gy) during breast-conserving surgery. IOERT has the longest evidence of all IORT techniques. When administered as a boost, excellent low local recurrence rates were observed in long-term follow-up >5 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062668PMC
July 2018
5 Reads

The Role of Brachytherapy in the Treatment of Breast Cancer.

Breast Care (Basel) 2018 Jul 29;13(3):157-161. Epub 2018 May 29.

Department of Radiotherapy, Medical University of Vienna, Vienna, Austria.

Radiotherapy plays an important part in the management of breast cancer. Especially after breast-conserving surgery, external whole breast irradiation, occasionally with an additional local boost, is an integral part of breast conservation. Besides external radiation techniques, brachytherapy (BT) has long been among the treatment options, especially with regard to local boost application. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062670PMC
July 2018
16 Reads

Advances in Breast Radiotherapy: Brachytherapy, Intraoperative Electron Therapy, Protons, and Nodal Irradiation.

Authors:
Joachim Widder

Breast Care (Basel) 2018 Jul 13;13(3):155-156. Epub 2018 Jun 13.

Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490303DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062693PMC
July 2018
1 Read

ABC4 Consensus: Assessment by a German Group of Experts.

Breast Care (Basel) 2018 Mar 15;13(1):48-58. Epub 2018 Feb 15.

University Hospital and Polyclinic of Gynecology, Martin Luther University, Halle (Saale), Germany.

The Advanced Breast Cancer Fourth Consensus (ABC4) on diagnosis and treatment of advanced breast cancer (ABC) again took place in Lisbon, on November 2-4, 2017, and was chaired by Fatima Cardoso, MD, PhD. This year's contents focused very much on new developments in the treatment of ABC. For example, the significance of inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) in hormone receptor (HR)-positive ABC, of dual antibody blockade in human epidermal growth factor receptor 2 (HER2)-positive ABC, and of poly(ADP-ribose) polymerase (PARP) inhibition in triple-negative ABC, as well as the potential therapeutic consequences, were discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016060PMC
March 2018
24 Reads
0.910 Impact Factor

Dystrophic Calcifications in the Breast from Secondary Hyperparathyroidism.

Breast Care (Basel) 2018 Mar 12;13(1):44-46. Epub 2018 Jan 12.

Department of Surgery, Ewha Womans University, School of Medicine, Seoul, Republic of Korea.

Background: Soft tissue calcification is common in patients with secondary hyperparathyroidism who have received long-term treatment with hemodialysis. However, calcifications in the breast parenchyma are not common. We report a case of a woman with dystrophic breast calcifications from secondary hyperparathyroidism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000484198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016053PMC
March 2018
10 Reads

Why Do Women with Breast Cancer Get Diagnosed and Treated Late in Sub-Saharan Africa? Perspectives from Women and Patients in Bamako, Mali.

Breast Care (Basel) 2018 Mar 31;13(1):39-43. Epub 2018 Jan 31.

Institute for Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.

Background: Breast cancer, the most common cancer among women worldwide, has a high mortality rate in low-income countries. In sub-Saharan Africa, most breast cancer patients are diagnosed with advanced disease. Some studies have quantified the time delay to diagnosis in sub-Saharan Africa, but very few have used qualitative methods to understand barriers leading to delay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000481087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016059PMC
March 2018
21 Reads

Differentiation between Pure Mucinous Breast Carcinomas and Fibroadenomas with Strong High-Signal Intensity on T2-Weighted Images from Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Breast Care (Basel) 2018 Mar 13;13(1):32-37. Epub 2017 Dec 13.

Department of Epidemiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.

Objective: This study aimed to identify characteristics that can differentiate between pure mucinous breast carcinomas (PMBCs) and fibroadenomas (FAs) with strong high-signal intensity on T2-weighted images (T2-SHi) from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

Methods: The DCE-MRI tumor characteristics were compared and analyzed between 35 PMBCs and 70 FAs with T2-SHi.

Results: Multivariate analysis revealed that delayed enhancement pattern was the only significant independent predictor (p = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000479955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016057PMC
March 2018
8 Reads

Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions.

Authors:
Joachim Bischoff

Breast Care (Basel) 2018 Mar 20;13(1):27-31. Epub 2018 Feb 20.

Center for Clinical Trials, Städtisches Klinikum Dessau, Dessau, Germany.

Antineoplastic agents directly targeting tumor cells have represented the major strategy of systemic anticancer therapy for many years. Nevertheless, overcoming resistance mechanisms remains a great challenge because treatment options are limited in many cases. From this point of view, immunotherapeutic approaches seem promising in a broad spectrum of solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016055PMC
March 2018
18 Reads

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies.

Breast Care (Basel) 2018 Mar 31;13(1):22-26. Epub 2018 Jan 31.

Universitätsfrauenklinik Heidelberg, Heidelberg, Germany.

Immunotherapies are set to become part of the therapeutic repertoire for breast cancer in the near future. Active vaccination is a promising strategy, especially in tumors that have a specific tumor-associated antigen. Although cellular immunotherapies have not yet shown efficacy, new technologies are on the way to improve this approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016061PMC
March 2018
1 Read

The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.

Breast Care (Basel) 2018 Mar 2;13(1):16-21. Epub 2018 Feb 2.

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

While detailed analysis of aberrant cancer cell signaling pathways and changes in cancer cell DNA has dominated the field of breast cancer biology for years, there now exists increasing evidence that the tumor microenvironment (TME) including tumor-infiltrating immune cells support the growth and development of breast cancer and further facilitate invasion and metastasis formation as well as sensitivity to drug therapy. Furthermore, breast cancer cells have developed different strategies to escape surveillance from the adaptive and innate immune system. These include loss of expression of immunostimulatory molecules, gain of expression of immunoinhibitory molecules such as PD-L1 and HLA-G, and altered expression of components involved in apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016054PMC

TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes.

Breast Care (Basel) 2018 Mar 15;13(1):8-14. Epub 2018 Feb 15.

Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany.

Background: Despite advancements in the treatment of primary and metastatic breast cancer, many patients lack a durable response to these treatments. Patients with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2(HER2)-positive breast cancer who do not have a pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) have a very poor prognosis. Tumor-infiltrating lymphocytes (TILs) have been identified as a predictive marker for pCR after NACT in TNBC and HER2-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016056PMC
March 2018
13 Reads